This invention relates to a wound dressing comprising a modified polymer, wherein the modified polymer comprises a polymer backbone covalently coupled to a compound of Formula (I): (I). X is a covalent bond or a linker; R11-32-31-31-31-31-3 haloalkyl and CN; and n is 0, 1, 2 or 3. Also provided are a methods of making the wound dressing and uses of such a wound dressing. The invention also relates to a method for detecting the presence of bacteria in a wound comprising applying the aforementioned wound dressing to the wound and a method of forming a modified polysaccharide, said polysaccharide allowing for the detection of bacteria in a wound when part of a wound dressing.
Methods of determining the platelet-derived growth factor (PDGF) sensitivity of cancer cells, and populations of PDGF sensitive 3D cancer cells obtainable by such methods are provided. Also provided are methods of targeting platelet-derived growth factor receptor (PDGFR) signalling in 3D cancer cells; methods of identifying a cancer treatment for a patient; methods of screening one or more compounds for PDGFR inhibition; and methods of treating a tumour using said methods of screening. Also provided are uses of a 3D cell culture to identify and target PDGFR signalling in a tumour; compositions comprising 3D cancer cells and PDGF; and compositions comprising 3D cancer cells and a compound that is a PDGFR inhibitor.
A transdermal patch is provided, wherein the patch comprises a cross-linked poly(ethylene oxide) hydrogel loaded with naltrexone, or a pharmaceutically acceptable salt or solvate thereof, and an occlusive adhesive tape. The poly(ethylene oxide) hydrogel has a crosslink density of at least 4.5×10−4 mol cm−3 and not more than 16×10−4 mol cm−3. Also provided are methods for preparing naltrexone-loaded cross-linked poly(ethylene oxide) hydrogels, transdermal patches for use as a medicament, for example in the treatment of a specified condition with LDN therapy.
C07C 327/30 - Esters of monothiocarboxylic acids having sulfur atoms of esterified thiocarboxyl groups bound to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms, not being part of nitro or nitroso groups
A transdermal patch is provided, wherein the patch comprises a cross-linked poly(ethylene oxide) hydrogel loaded with naltrexone, or a pharmaceutically acceptable salt or solvate thereof, and an occlusive adhesive tape. The poly(ethylene oxide) hydrogel has a crosslink density of at least 4.5×10-4mol cm-3and not more than 16×10-4mol cm-3. Also provided are methods for preparing naltrexone-loaded cross-linked poly(ethylene oxide) hydrogels, transdermal patches for use as a medicament, for example in the treatment of a specified condition with LDN therapy.
Methods are provided for the synthesis of a compound of formula (X). R21424144-aryl; R3144-alkyl; and A is a pharmaceutically acceptable anion (e.g.a halide). Also provided are intermediate compounds formed during the synthesis.
C07C 327/30 - Esters of monothiocarboxylic acids having sulfur atoms of esterified thiocarboxyl groups bound to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms, not being part of nitro or nitroso groups
7.
PRODUCTION PROCESSES OF S-AND O-DIACYLATED GAMMA-GLUTAMYL-CYSTEAMINE PRODRUGS
Methods are provided for the synthesis of a compound of formula (X). R2 is selected from -H, -C1-C4-alkyl,-C2-C4-alkenyl and C1-C4-aryl; R3 is selected from -C(O)H and -C(O)C1-C4-alkyl; and A is a pharmaceutically acceptable anion (e.g.a halide). Also provided are intermediate compounds formed during the synthesis.
C07C 327/30 - Esters of monothiocarboxylic acids having sulfur atoms of esterified thiocarboxyl groups bound to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms, not being part of nitro or nitroso groups
8.
METHOD OF FORMING GRAPHENE NANOPLATELETS, GRAPHENE NANOPLATELETS SO-OBTAINED AND COMPOSITES COMPRISING SAID NANOPLATELETS
Provided is a method of forming graphene nanoplatelets, comprising: providing an aqueous suspension comprising expanded graphite; and subjecting the suspension to exfoliation, wherein the exfoliation comprises sequential treatments of sonication and high shear mixing, thereby forming graphene nanoplatelets. Also provided is a method of forming an expanded graphite, comprising obtaining an expandable graphite and heating the expandable graphite in flowing gas at a temperature of at least 600°C. Also provided are graphene nanoplatelets obtainable or obtained by the said method of forming graphene nanoplatelets, a plastics composite comprising the graphene nanoplatelets, a vehicle or structure comprising such a composite, and use of such graphene nanoplatelets in a plastics composite.
The application relates to an electrode comprising a support and metal oxide catalyst, wherein the metal oxide catalyst comprises a nanoforest structure. Also provided is a composition comprising a support and hydrated metal oxide catalyst precursor, wherein the metal oxide catalyst precursor comprises a nanoforest structure. Also provided is a method of making an electrode and of making a composition that is useful as an electrode precursor. Also provided is a fuel cell comprising a said electrode. Use in a fuel cell of an electrode of the invention is also provided.
The present subject matter relates generally to compounds having the formula (I): wherein each of X, Y, R1, R2, R3, R4, and n are as defined herein. Compounds of formula (I) may act as inhibitors of the thioredoxin reductase enzyme system. The subject matter also relates to use, formulation and preparation of the compounds. The compounds may be useful in the treatment of inflammatory and oxidative diseases and conditions. The compounds may also provide useful anti-proliferative and anti- apoptotic effects.
A61K 31/235 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
A61K 31/277 - NitrilesIsonitriles having a ring, e.g. verapamil
A61K 31/341 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
A61K 31/63 - Compounds containing para-N-benzene- sulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonohydrazide
C07C 307/10 - Diamides of sulfuric acids having nitrogen atoms of the sulfamide groups bound to carbon atoms of six-membered aromatic rings
C07C 311/21 - Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
C07C 311/29 - Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
C07C 311/44 - Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
C07D 407/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 239/54 - Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
11.
AN APPARATUS AND METHOD FOR PROVIDING INFORMATION TO A VISUALLY AND / OR HEARING IMPAIRED OPERATOR
A method and apparatus for providing information to an operator of a device, such as a currency dispensing machine, is disclosed. The apparatus includes a surface, for example a keypad, that is touched by an operator. The keys of the keypad vibrate in response to an input signal. By reference to a reference location, a centrally located key, the vibration indicates to the operator a direction. Variation in the intensity or duration of vibration pulses is also used to indicate distance or can be used to provide other information.
G09B 21/00 - Teaching, or communicating with, the blind, deaf or mute
G07F 7/00 - Mechanisms actuated by objects other than coins to free or to actuate vending, hiring, coin or paper currency dispensing or refunding apparatus
G07F 17/00 - Coin-freed apparatus for hiring articlesCoin-freed facilities or services
G07F 19/00 - Complete banking systemsCoded card-freed arrangements adapted for dispensing or receiving monies or the like and posting such transactions to existing accounts, e.g. automatic teller machines
12.
MELATONIN DERIVATIVES AND THEIR USE AS ANTIOXIDANTS
The present subject matter relates generally to antioxidant compounds having the formula (I): wherein each of R1, R2, R3, and R4 are as defined below. These compounds are potentially useful as, for example, antioxidants.
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
A61K 31/4045 - Indole-alkylaminesAmides thereof, e.g. serotonin, melatonin
A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
The present invention provides a coating composition comprising an aqueous medium and, dispersed therein, starch and a film-forming agent which controls swelling of the starch by the aqueous medium. Formulations comprising the coating composition are also provided. The formulations may be useful in the treatment or diagnosis of colonic disease.
The present invention provides a pellet formulation comprising colloidal silicon dioxide (CSD) and one or both of a surfactant and a plasticiser. A process for the production of 5 said formulation is also provided.
patents
